GALECTIN THERAPEUTICS INC - COM NEW (GALT)

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Equity / COM NEW
Total 13F shares
9,746,940
Share change
+218,685
Total reported value
$26,802,643
Put/Call ratio
171%
Price per share
$2.75
Number of holders
84
Value change
+$624,662
Number of buys
30
Number of sells
21

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2024

As of 30 Sep 2024, GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by 84 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 9,746,940 shares. The largest 10 holders included VANGUARD GROUP INC, BlackRock, Inc., OSAIC HOLDINGS, INC., GEODE CAPITAL MANAGEMENT, LLC, COMMONWEALTH EQUITY SERVICES, LLC, Wealthspire Advisors, LLC, Geneos Wealth Management Inc., STATE STREET CORP, MORGAN STANLEY, and NORTHERN TRUST CORP. This page lists 78 institutional shareholders reporting positions in this security for the Q3 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.